Sanofi

Open: 47.44 Close: 47.29 Change: -0.15

The best way to get informed about Sanofi Stock without reading hundreds of pages.

This document will help you to evaluate Sanofi without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, SA, year, merge, SanofiAventis, target, US, and the …

Concept Map

Semantic Network

Stock Summary

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company also provides cough, cold.

Today's Summary

Sanofi S.A. was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélélabos. In 2004, Sanofi merged with Aventis and renamed Sanofi in 2011.

Today's News

Sanofi S.A. was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélélabos. In 2004, Sanofi merged with Aventis and renamed to Sanofi in May 2011. Sanofi-Aventis agreed to pay Regeneron $100 million per year for five years to create new biopharmaceuticals. Sanofi joined the bidding for Merck & Co.s over-the-counter health-products unit. In January 2021, Sanofi announced that it would buy the British biotech Kymab Ltd and its potential first-in-class drug candidate – KY1005 –- for $1.45 billion. In April 2022, a $638m vaccine and enzymes production facility in Tuas , Singapore, targeted for completion in 2025. Sanofi broke ground on its biggest industrial investment in April 2022. Sanofis previous head office was located in the 13th arrondissement of Paris. After Sanofi and Aventis merged, the employees at the former Aventi head office in Schiltigheim, Alsace moved to Paris. Sanofi-Aventis: A timeline of biopharma deals. Sanofi Expands Regeneron Deal. Sanofi: Press Releases, Monday, December 9, 2019. Sanofi-Aventis, Charite University sign cooperation agreement. Sanofi and GSK land $2.1 billion deal with U.S. for Covid-19 vaccine development and 100 million doses. J.P. Morgan analyst Richard Vosser maintains a Hold rating on Sanofi today and set a price target of EUR94.00. Currently, the analyst consensus is a Moderate Buy with an average price target $100.00. Currently, Sanofi is a moderate Buy. Sanofi SA (EPA: SAN) is gaining at writing following a report that buyout firms have shown interest in buying its consumer health unit. Sanofi announces today the filing of its Form 20-F. Sanofis fourth-quarter operating income declined 5%. Sanofi SA (SNW.BE) stock price, news, quote & history - yahoo finance.be) Stock Price, News, Quote & History - Yahoo Finance. Sanofi CEO Paul Hudsons salary takes another dip to €10.57 million - ceoworld magazine. CEO Paul Hudsons pay package has seen a reduction for the third consecutive year. Sanofi approach to executive compensation may encourage other corporations to reconsider their own policies. The future job holder will also play an important ambassadorial role and will develop a network to forge key working relationships internally and externally. The position will represent Sanofi within the medical research community through involvement in international scientific meetings and through professional publications. Eohilia is the only oral therapy approved for patients 12 and above in the US. Bristol Myers Squibb s intravenous cendakimab, as well as Ellodi Pharmaceuticals oral fluticasone propionate, are in Phase III clinical trials for EoE in the U.S. Eohili is only oral drug approved for those aged 12 and older. Sanofi-Denali RIPK1 collaboration hit an early bump in the road when the partners switched to a backup compound in response to chronic toxicity data. Sanofi stopped work on cutaneous lupus erythematosus last year. The findings will form the basis for a phase 3 program in the severe inflammatory condition. Sanofi named one of the winners of the 2024 REBRAND 100 Global Award. Pfizer, GSK, J&J and Novartis followed on after the Big Pharmas in launching their own corporate rebrands. Sanofi SA (SNW) has delivered solid sales and business EPS growth at CER. François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee. Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more than a decade. Takeda quickly follows Sanofi-Regeneron with esophagitis approval Feb. 26, 2024.

Stock Profile

"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France."

Keywords

The game is changing. There is a new strategy to evaluate Sanofi fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, SA, year, merge, SanofiAventis, target, US, and the most common words in the summary are: sanofi, company, vaccine, trial, market, event, new, . One of the sentences in the summary was: was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélélabos. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sanofi #company #vaccine #trial #market #event #new.